ENDOCYTE INC's ticker is and the CUSIP is 29269A902. A total of 3 filers reported holding ENDOCYTE INC in Q1 2014. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2018 | $1,186,000 | +36.8% | 66,800 | +6.4% | 0.01% | +28.6% |
Q2 2018 | $867,000 | -61.5% | 62,800 | -74.6% | 0.01% | -69.6% |
Q1 2018 | $2,251,000 | +1965.1% | 247,600 | +871.0% | 0.02% | +2200.0% |
Q4 2017 | $109,000 | +505.6% | 25,500 | +96.2% | 0.00% | – |
Q3 2017 | $18,000 | -10.0% | 13,000 | 0.0% | 0.00% | – |
Q2 2017 | $20,000 | -48.7% | 13,000 | -14.5% | 0.00% | – |
Q1 2017 | $39,000 | -62.5% | 15,200 | -62.6% | 0.00% | -100.0% |
Q4 2016 | $104,000 | -33.3% | 40,600 | -19.4% | 0.00% | -50.0% |
Q3 2016 | $156,000 | +90.2% | 50,400 | +96.9% | 0.00% | +100.0% |
Q2 2016 | $82,000 | +4000.0% | 25,600 | +4166.7% | 0.00% | – |
Q1 2016 | $2,000 | -81.8% | 600 | -77.8% | 0.00% | – |
Q4 2015 | $11,000 | -95.8% | 2,700 | -95.3% | 0.00% | -100.0% |
Q3 2015 | $261,000 | +46.6% | 56,900 | +66.4% | 0.00% | +100.0% |
Q2 2015 | $178,000 | -72.2% | 34,200 | -66.5% | 0.00% | -80.0% |
Q1 2015 | $640,000 | +932.3% | 102,200 | +932.3% | 0.01% | +900.0% |
Q4 2014 | $62,000 | -93.3% | 9,900 | -93.5% | 0.00% | -92.9% |
Q3 2014 | $927,000 | -40.5% | 152,400 | -35.6% | 0.01% | -41.7% |
Q2 2014 | $1,559,000 | -84.5% | 236,600 | -44.1% | 0.02% | -85.8% |
Q1 2014 | $10,072,000 | +3912.7% | 423,000 | +1700.0% | 0.17% | +4125.0% |
Q4 2013 | $251,000 | -36.8% | 23,500 | -21.1% | 0.00% | -50.0% |
Q3 2013 | $397,000 | +2.6% | 29,800 | +1.0% | 0.01% | -20.0% |
Q2 2013 | $387,000 | – | 29,500 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GROUP ONE TRADING, L.P. | 423,000 | $10,072,000 | 0.17% |
SABBY MANAGEMENT, LLC | 154 | $367,000 | 0.02% |
Citadel Advisors | 51,700 | $1,231,000 | 0.00% |